Pharma BD Deal Intelligence
Shire's $260M upfront for Lumena cancelled a planned $75M IPO and signaled aggressive rare-disease pipeline expansion alongside the prior ViroPharma and…
The deal strengthens Shire's rare-disease leadership and leverages its existing $800M+ GI infrastructure; LUM001 had potential 2016 approval visibility.
Mirum bought maralixibat back from Shire for $120M after Shire de-prioritized the asset post-Takeda merger speculation — a signal that the original Lumena…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Shire acquired privately held Lumena Pharmaceuticals for $260M upfront plus near-term contingent milestones, adding two oral ASBT inhibitors—LUM001 in Phase 2 across four orphan cholestatic indications and LUM002 ready to enter Phase 2 in NASH. Strengthened Shire's GI/hepatic rare-disease franchise.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Shire plc / Lumena Pharmaceuticals, Inc. (this deal) | 2014 | $260M | 21 |
| Shire plc / Dyax Corp. | 2016 | $5.9B | 89 |
| Shire plc / New River Pharmaceuticals Inc. | 2007 | $2.6B | 88 |
| Shire plc / Jerini AG | 2008 | $521M | 85 |
| Shire plc / NPS Pharmaceuticals | 2015 | $5.2B | 78 |
| Shire plc / Baxalta Inc. | 2016 | $32.0B | 77 |
| Shire plc / ViroPharma Incorporated | 2013 | $4.2B | 58 |
← Browse all deals · How we score deals
More: 2014 deals · Shire plc deals · Gastroenterology deals